|
|
||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 95, 216-222, Copyright © 1988 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
KF Lee, J Mandell, JS Rankin, LH Muhlbaier and AS Wechsler
Of all patients with acute evolving myocardial infarction treated
surgically at Duke University Medical Center between 1984 and 1986, 27
patients given high doses (greater than 1.5 million units) of streptokinase
preoperatively were studied. Eleven patients who received streptokinase had
coronary bypass grafting 12 hours after thrombolytic therapy (early hours),
eight patients between 12 and 72 hours (delayed), and eight patients beyond
72 hours (late hours). Seventeen patients who underwent coronary bypass
grafting within 6 hours of the onset of symptoms, without preoperative
streptokinase, were included as control patients. Only the patients having
early operation had significantly greater postoperative blood loss;
postoperative use of red blood cells; fresh-frozen plasma; cryoprecipitate;
prolonged postoperative prothrombin time; and prolonged partial
thromboplastin time. Patients having delayed or late operations did not
differ significantly from patients not receiving streptokinase. Only the
interval between time of streptokinase administration and operation could
account for the coagulopathy and the postoperative bleeding complications
in the early group. Patients in the early group had a higher in-hospital
mortality (27% versus 6% for the non-streptokinase group) and major
noncardiac morbidity (36% versus 12% for the non- streptokinase group).
Patients in the delayed and late groups had minimal postoperative
complications and no mortality. Observations were not explained by
differences in total ischemic time, number of angioplasty failures, or
number of patients with cardiogenic shock between the early group and the
non-streptokinase group. Postoperative bleeding and massive use of blood
products seemed to be contributory factors: Two of three deaths in the
patients having early operations were associated with clinical suspicion of
tamponade. Patients undergoing coronary bypass grafting within 12 hours of
streptokinase therapy appear to be a high-risk group in a more emergent,
uncontrolled clinical setting and require aggressive monitoring and
correction of coagulopathy.
ARTICLES
Immediate versus delayed coronary grafting after streptokinase treatment. Postoperative blood loss and clinical results
Department of Surgery, Duke University Medical Center, Durham, N.C. 27710.
This article has been cited by other articles:
![]() |
Y. Shapira, I. Herz, M. Vaturi, A. Porter, Y. Adler, Y. Birnbaum, B. Strasberg, S. Sclarovsky, and A. Sagie Thrombolysis is an effective and safe therapy in stuck bileaflet mitral valves in the absence of high-risk thrombi J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1874 - 1880. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Goldman and M. J. Eisenberg Identification and Management of Patients with Failed Thrombolysis after Acute Myocardial Infarction Ann Intern Med, April 4, 2000; 132(7): 556 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Lanzkron and W. R. Bell State-of-the-Art Review : Management of Patients Who Require Invasive Procedures Immediately Following Thrombolytic Therapy Clinical and Applied Thrombosis/Hemostasis, July 1, 1996; 2(3): 158 - 163. [Abstract] [PDF] |
||||
![]() |
J. C. Nicolau, R. V. Ardito, S. A. C. Garzon, M. A. F. V. Pinto, P. R. Nogueira, A. M. Lorga, and J. L. B. Jacob Surgical revascularization after fibrinolysis in acute myocardial infarctionLong-term follow-up J. Thorac. Cardiovasc. Surg., June 1, 1994; 107(6): 1454 - 1459. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |